The approval is another example of so-called tissue-agnostic indications, which are based on a cancer’s genetic signature ...
A “practically clean” version of the bill will allow the FDA to continue its review and testing programs, while leaving more ...
The British drugmaker decided the medicine, which works similarly to Novartis’s Leqvio, wasn’t potent enough to justify ...
Committee members voted in support of Rebiotix’s treatment for recurrent C. diff infections of the intestines, a condition ...
Concerns over blood clotting risk had derailed testing of the hemophilia treatment last year, leading the companies to adjust ...
The French drugmaker terminated a nearly decade-old deal that helped Allogene emerge as the sector's largest "off-the-shelf" ...
The British drugmaker is investing in Spero Therapeutics and acquiring most of the rights to an oral antibiotic the FDA ...
The deal results from a strategic review Sesen, formerly known as Eleven Biotherapeutics, undertook after the FDA rejected ...
The grant is one of the Novo Nordisk Foundation’s largest and will fund a 12-year research collaboration to construct a ...
The therapy, called Skysona and cleared to treat cerebral adrenoleukodystrophy, is the product of more than a decade of work ...
When the company debuted in March, it announced plans to hire 200 employees over two years. Now, it’s laid off nearly half ...
Rocket is acquiring Renovacor at a roughly 75% discount to its public debut price last year, when it became one of dozens of ...